Steroid therapy for a case of severe drug-induced cholestasis

被引:19
作者
Giannattasio, Antonietta [1 ]
D'Ambrosi, Mariangela [1 ]
Volpicelli, Monica [1 ]
Iorio, Raffaele [1 ]
机构
[1] Univ Naples Federico II, Dept Pediat, I-80131 Naples, Italy
关键词
corticosteroid therapy; drug-induced hepatotoxicity;
D O I
10.1345/aph.1G345
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
OBJECTIVE: TO report a severe case of cholestatic liver disease successfully treated with corticosteroids following combined therapy with clarithromycin and nimesulide. CASE SUMMARY: A 15-year-old girl was admitted with cholestasis probably related to treatment with clarithromycin and nimesulide for an upper respiratory tract infection. Other causes of liver disease (infections, metabolic liver disorders, genetic cholestatic syndromes, autoimmune diseases, primary biliary tract disorders) were excluded. Liver biopsy showed a severe canalicular cholestasis with bile plugs in dilated bile canaliculi, giant cell transformation, and portal and lobular infiltrate. An objective causality assessment suggested that cholestasis was probably related to clarithromycin and/or nimesulide use. No benefit was derived from a course of ursodeoxycholic acid therapy. Since the patient experienced a progressive worsening in cholestasis, prednisone was started after 20 days. This therapy was promptly followed by improvement in clinical and laboratory test results. After 2 months of prednisone treatment, the patient became symptom-free with normal liver function tests. DISCUSSION: The manifestations of drug-induced hepatotoxicity are highly variable, ranging from asymptomatic hypertransaminemia to fulminant hepatic failure. No specific treatment for drug-induced hepatotoxicity exists. Early recognition and drug withdrawal are the keys to management of hepatotoxicity, but in some cases, liver disease may persist despite discontinuation of the drug. Possible advantages of corticosteroid therapy have not been well demonstrated. CONCLUSIONS: Application of the Naranjo probability scale indicates a probable relationship between cholestasis and nimesulide plus clarithromycin use. This case draws attention to a possible therapeutic option for some cases of drug-induced hepatotoxicity that show a severe course without any sign of improvement.
引用
收藏
页码:1196 / 1199
页数:4
相关论文
共 22 条
[1]
Alberti L, 2002, AM J GASTROENTEROL, V97, P1072
[2]
BOESTERLI UA, 2002, DRUG SAFETY, V25, P633
[3]
CLARITHROMYCIN-INDUCED HEPATOTOXICITY [J].
BROWN, BA ;
WALLACE, RJ ;
GRIFFITH, DE ;
GIRARD, W .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :1073-1074
[4]
Azithromycin-induced intrahepatic cholestasis [J].
Chandrupatla, S ;
Demetris, AJ ;
Rabinovitz, M .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (10) :2186-2188
[5]
Drug-induced liver disease [J].
Shivakumar Chitturi ;
Geoffrey C. Farrell .
Current Treatment Options in Gastroenterology, 2000, 3 (6) :457-462
[6]
Surveillance for fatal suspected adverse drug reactions in the UK [J].
Clarkson, A ;
Choonara, I .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 (06) :462-466
[7]
Progressive cholestatic liver disease associated with clarithromycin treatment [J].
Fox, JC ;
Szyjkowski, RS ;
Sanderson, SO ;
Levine, RA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (06) :676-680
[8]
Antibacterial-induced hepatotoxicity - Incidence, prevention and management [J].
George, DK ;
Crawford, DHG .
DRUG SAFETY, 1996, 15 (01) :79-85
[9]
Giordano N, 2001, ANN PHARMACOTHER, V35, P1053
[10]
Drug-induced liver injury [J].
Kaplowitz, N .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S44-S48